Evaluation of Two Commercial Enzyme-Linked Immunosorbent Assay Kits for the Detection of Human Circulating Metrnl

Zheng, Si-Li; Li, Zhiyong; Zhang, Zheng; Wang, Dongsheng; Xu, Jian

doi:10.1248/cpb.c17-00846

Cited by 18 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been several reported studies on the association between serum levels of Metrnl in type 2 diabetes mellitus (T2DM), the findings have been conflicting. Lee et al [13] and Zheng et al [14] reported lower serum levels of Metrnl in patients with newly diagnosed T2DM, whereas Chung et al [15] reported increased serum levels of Metrnl, which was consistent with the findings of the present study. Because of the limited number of studies on the association between T2DM and serum levels of Metrnl, it is difficult to explain these conflicting findings.…”

Section: Discussionsupporting

confidence: 92%

“…The findings of previously published studies have shown that serum levels of Metrnl are increased in patients with T2DM, but the findings are controversial. Lee et al [13] and Zheng et al [14] reported lower serum levels of Metrnl in patients with newly diagnosed T2DM, while Chung et al [15] identified increased serum levels of Metrnl. Also, in preclinical studies, the effects of Metrnl on adipose tissue in mice showed that expression of Metrnl by adipocytes could increase insulin sensitivity by stimulating the peroxisome proliferator-activated receptor gamma (PPARγ) pathway [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Wang

Deng

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

Background Meteorin-like (Metrnl) is a novel adipomyokine that may improve glucose tolerance and affect insulin resistance. This study aimed to investigate the association between serum levels of Metrnl with blood glucose status and to its association with insulin resistance. Material/Methods The study included 160 subjects with normal glucose tolerance (NGT) (n=40), impaired fasting glucose (IFG) (n=40), impaired glucose tolerance (IGT) (n=40), and newly diagnosed type 2 diabetes mellitus (T2DM) (n=40). An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of Metrnl. Partial correlation analysis was used to analyze the relationship between serum levels of Metrnl and metabolic parameters. Multiple logistic regression analysis was performed to identify the association between serum levels of Metrnl with the risk of diabetes. Results Serum levels of Metrnl was highest in patients with T2DM and significantly increased in patients with prediabetes compared with individuals with NGT. After adjusting for age, gender, and body mass index (BMI), serum Metrnl level was significantly correlated with lipid profile, glucose profile, and insulin resistance. Multiple logistic regression analysis showed that Metrnl significantly increased the risk of T2DM (OR=1.727; P=0.008) before adjusting for the homeostatic model assessment of insulin resistance (HOMA-IR). When further adjusted for HOMA-IR, Metrnl was no longer associated with an increased OR for T2DM (OR=1.491; P=0.066), while the HOMA-IR significantly increased the risk of T2DM (OR=1.935; P=0.008). Conclusions Serum levels of Metrnl were significantly increased in patients with T2DM and may increase the risk of T2DM independent of insulin resistance.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Wang

Deng

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…As shown in Table 1, some studies show that blood Metrnl levels are increased in type 2 diabetes when compared with nondiabetes, including the studies of Chung et al [13], AlKhairi et al [20], Wang et al [11], etc., whereas other studies have drawn the opposite conclusion that blood Metrnl is reduced in type 2 diabetes, including the studies of Lee et al [21], Dadmanesh et al [14] and our laboratory [22]. Consistent with the reduced Metrnl level in type 2 diabetes, El-Ashmawy et al's study also showed that blood Metrnl is negatively correlated with HOMA-IR and HbA1c [23].…”

Section: Metrnl In Type 2 Diabetes Mellitussupporting

confidence: 71%

Involvement of the secreted protein Metrnl in human diseases

Miao

et al. 2020

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

Metrnl, a secreted protein expressed in white adipose tissue, has been identified as a novel adipokine. It is also highly expressed in barrier tissues, including the skin, intestinal and respiratory tract epithelium in both mice and humans. Research shows that its expression is upregulated by inflammation, chronic high-fat diets, exercise, cold exposure, etc., and it plays important roles in promoting neurite extension, enhancing white fat browning, improving insulin sensitivity, modulating lipid metabolism and regulating inflammatory response, the latter implying Metrnl is a new cytokine. These studies suggest that Metrnl could be a promising biomarker and a potential therapeutic target for the related diseases. For proving this, clinical studies need to be performed to bridge the gap between bench and bedside. In this paper, we summarize the progress in recent clinical research on Metrnl. Most of these clinical studies are designed to confirm the relationship between circulating Metrnl and metabolic or cardiovascular disease (type 2 diabetes and coronary heart disease), or immune inflammation-related diseases, such as colitis, psoriasis and arthritis. Although blood Metrnl seems to fluctuate and are affected by many factors, such as drugs, physical exercise, and cold exposure, these clinical studies provide reliable clues that Metrnl is associated with coronary heart disease, inflammationrelated diseases, etc. Nevertheless, the roles of Metrnl in some diseases such as nervous system diseases remain unclear, and its putative involvement should be further clarified. These studies could promote the application of Metrnl in clinic as a new therapeutic target.

show abstract

“…Serum samples were obtained as previously described [ 21 ]. The levels of IL-1β, IL-6, and TNF-α in serum samples were quantified using commercial ELISA kits (R&D system, New York, NY, USA).…”

Section: Methodsmentioning

confidence: 99%

Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells

Zhang

Wang

et al. 2020

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

Metrnl is a newly identified secreted protein highly expressed in the intestinal epithelium. This study aimed to explore the role and mechanism of intestinal epithelial Metrnl in ulcerative colitis. Metrnl −/− (intestinal epithelial cell-specific Metrnl knockout) mice did not display any phenotypes of colitis under basal conditions. However, under administration of 3% dextran sodium sulfate (DSS) drinking water, colitis was more severe in Metrnl −/− mice than in WT mice, as indicated by comparisons of body weight loss, the presence of occult or gross blood per rectum, stool consistency, shrinkage in the colon, intestinal damage, and serum levels of inflammatory factors. DSS-induced colitis activated autophagy in the colon. This activation was partially inhibited by intestinal epithelial Metrnl deficiency, as indicated by a decrease in Beclin-1 and LC3-II/I and an increase in p62 in DSS-treated Metrnl −/− mice compared with WT mice. These phenomena were further confirmed by observation of autophagosomes and immunofluorescence staining for LC3 in epithelial cells. The autophagy-related AMPK-mTOR-p70S6K pathway was also activated in DSS-induced colitis, and this pathway was partially blocked by intestinal epithelial Metrnl deficiency, as indicated by a decrease in AMPK phosphorylation and an increase in mTOR and p70S6K phosphorylation in DSS-treated Metrnl −/− mice compared with WT mice. Therefore, Metrnl deficiency deteriorated ulcerative colitis at least partially through inhibition of autophagy via the AMPK-mTOR-p70S6K pathway, suggesting that Metrnl is a therapeutic target for ulcerative colitis.

show abstract

Evaluation of Two Commercial Enzyme-Linked Immunosorbent Assay Kits for the Detection of Human Circulating Metrnl

Cited by 18 publications

References 14 publications

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance

Involvement of the secreted protein Metrnl in human diseases

Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells

Contact Info

Product

Resources

About